title: Thrombopoietin regulates proliferation, apoptosis, secretory activity and intracellular messengers in porcine ovarian follicular cells: involvement of protein kinase A.
abstract: Thrombopoietin (TPO) is known to be involved in megakariocytopoesis, but its role in the control of ovarian function is unknown. The aims of this study were to determine whether TPO can regulate the proliferation, apoptosis and secretory activity of ovarian cells, to identify possible intracellular mediators of TPO action, especially protein kinase A (PKA), and to define their interrelationships within ovarian cells. We investigated the effect of TPO treatment (0, 1, 10 or 100 ng/ml) on the following characteristics of cultured porcine ovarian follicles, determined using SDS-PAGE and Western blotting, immunocytochemistry, RIA and ELISA: the expression of intracellular peptides associated with proliferation (PCNA), apoptosis (Bax), tyrosine kinase (TK, phosphotyrosine), Cdc2/p34 kinase, PKA and the transcription factor CREB-1, and the secretion of progesterone, androstenedione, estradiol-17beta, oxytocin, inhibin A, inhibin B, IGF-I, transforming growth factor-2beta (TGF-2beta) and IGF-binding protein 3 (IGFBP-3). The involvement of PKA-dependent pathways was examined by evaluating the effect of a PKA blocker (KT5720, 1 microg/ml), either alone or in combination with TPO, on the parameters listed above. A TPO-induced increase in expression of PCNA, Bax, PKA, TK, Cdc2/p34 and CREB was observed. Furthermore, TPO was able to inhibit androstenedione, estradiol, TGF-2beta and IGFBP-3 secretion, and to stimulate oxytocin, inhibin A, inhibin B and IGF-I secretion. Progesterone secretion was not stimulated. The PKA blocker KT5720, when given alone, reduced the expression of Bax and TGF-2beta, augmented the expression of PKA, CREB and oxytocin, but did not influence the secretion of progesterone, androstenedione, estradiol, IGFBP-3, inhibins A and B or IGF-I. When given together with TPO, the PKA blocker prevented or reversed the action of TPO on PKA, CREB, androstenedione, estradiol, IGFBP-3, oxytocin, but not its effect on Bax, TGF-2beta or inhibin B. On the other hand, treatment with KT5720 augmented the effect of TPO on progesterone, inhibin A and IGF-I. These results provide the first evidence that TPO may be a potent regulator of ovarian function (e.g. proliferation, apoptosis and the secretion of peptide hormones, steroids, growth factors and growth factor-binding protein, as well as of the expression of some intracellular messengers). Furthermore, they demonstrated the importance of PKA in controlling these functions and in mediating the effects of TPO on ovarian cells. It remains possible that other (TK- and Cdc2/p34-dependent) intracellular mechanisms are also involved in mediating TPO action on the ovary.
authors.affiliation: Research Institute of Animal Production, Hlohovská 2, 949 92 Nitra, Slovakia. sirotkin@vuzv.sk
authors.forename: A V
authors.initials: AV
authors.lastname: Sirotkin
authors.forename: P
authors.initials: P
authors.lastname: Sanislo
authors.forename: H-J
authors.initials: HJ
authors.lastname: Schaeffer
authors.forename: I
authors.initials: I
authors.lastname: Florkovicová
authors.forename: J
authors.initials: J
authors.lastname: Kotwica
authors.forename: J
authors.initials: J
authors.lastname: Bulla
authors.forename: L
authors.initials: L
authors.lastname: Hetényi
mesh_terms: D000735:Androstenedione / Q000378:metabolism; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D016203:CDC2 Protein Kinase / Q000378:metabolism; D002227:Carbazoles / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004958:Estradiol / Q000378:metabolism; D005260:Female; D015151:Immunoblotting / Q000379:methods; D007150:Immunohistochemistry / Q000379:methods; D007211:Indoles / Q000494:pharmacology; D007265:Inhibins / Q000378:metabolism; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D006080:Ovarian Follicle / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D010121:Oxytocin / Q000378:metabolism; D019000:Phosphotyrosine / Q000378:metabolism; D011374:Progesterone / Q000378:metabolism; D011758:Pyrroles / Q000494:pharmacology; D013552:Swine; D013926:Thrombopoietin / Q000494:pharmacology*; D016212:Transforming Growth Factor beta / Q000378:metabolism
chemical_list: D002227:Carbazoles; D007211:Indoles; D018972:Insulin-Like Growth Factor Binding Protein 3; D011758:Pyrroles; D016212:Transforming Growth Factor beta; C422362:inhibin A; C422364:inhibin B; D019000:Phosphotyrosine; D000735:Androstenedione; D011374:Progesterone; D004958:Estradiol; D010121:Oxytocin; D007265:Inhibins; C057416:KT 5720; D007334:Insulin-Like Growth Factor I; D013926:Thrombopoietin; D017868:Cyclic AMP-Dependent Protein Kinases; D016203:CDC2 Protein Kinase